Effect of FPL57787 in exercise-induced asthma.
In ten patients with extrinsic asthma the effects of a new oral chromone FPL57787 and placebo were studied in a random double-blind fashion to assess the effect of FPL57787 in preventing exercise-induced asthma (EIA). Exercise testing consisted of steady state running on an inclined treadmill for up to 8 min. FPL57787 gave significant protection (P less 0.01) compared to placebo from the maximum percentage fall in FEV1, FVC and MMEF after exercise. FPL57787 also produced a small but significant (P less than 0.01) percentage increase in FEV1 2 hr after the drug compared to placebo, whereas no significant increase was seen in FVC or in MMEF.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D001250:Asthma, Exercise-Induced / Q000188:drug therapy*; D002867:Chromones / Q000008:administration & dosage* / Q000627:therapeutic use; D004311:Double-Blind Method; D005541:Forced Expiratory Volume; D006801:Humans; D008450:Maximal Midexpiratory Flow Rate; D010919:Placebos; D013997:Time Factors; D014797:Vital Capacity
D002867:Chromones; D010919:Placebos; C020486:proxicromil